Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 4/20 | 0.31 |
| ▸ | PARP1 | P09874 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15520406 | 1.00 | UCHL1 (0.37) | UCHL1NR1H2ABCB1ALDH1A1CHRM2 | |
| SCHEMBL30538732 | 0.90 | NR1H2 (0.35) | NR1H2ABCB1ALDH1A1CHRM2CHRM1 | |
| SCHEMBL393307 | 0.87 | ALDH1A1 (0.38) | NR1H2ALDH1A1CHRM2CHRM1CHRM3 | |
| SCHEMBL1861180 | 0.87 | ALDH1A1 (0.38) | NR1H2ALDH1A1CHRM2CHRM1CHRM3 | |
| SCHEMBL1861179 | 0.87 | ALDH1A1 (0.38) | NR1H2ALDH1A1CHRM2CHRM1CHRM3 | |
| SCHEMBL3245496 | 0.86 | GPR119 (0.34) | NR1H2ABCB1ALDH1A1CHRM2CHRM1 | |
| SCHEMBL30530778 | 0.86 | NR1H2 (0.37) | NR1H2ABCB1ALDH1A1CHRM2CHRM1 | |
| SCHEMBL30732601 | 0.86 | ABCB1 (0.35) | NR1H2ABCB1ALDH1A1TSHRSRC | |
| SCHEMBL13938736 | 0.86 | GPR119 (0.34) | NR1H2ABCB1ALDH1A1CHRM2CHRM1 | |
| SCHEMBL15519418 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2708540-B1 | PYRIMIDO-DIAZEPINONE COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-9453021-B2 | Pyrimidodiazepinone compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20140171422-A1 | PYRIMIDODIAZEPINONE COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-06-19 | — | — | US | disclosed |
| EP-2708540-A1 | PYRIMIDO-DIAZEPINONE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2014-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171422-A1 | PYRIMIDODIAZEPINONE COMPOUND | REN, AGTR1, KCNJ1 | UCHL1 4316/4885NR1H2 666/4885ABCB1 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.